iBio Inc. (IBIO)
NASDAQ: IBIO
· Real-Time Price · USD
0.73
0.02 (2.47%)
At close: Jun 24, 2025, 3:59 PM
0.76
3.70%
After-hours: Jun 24, 2025, 06:08 PM EDT
2.47% (1D)
| Bid | 0.72 |
| Market Cap | 12.07M |
| Revenue (ttm) | 375K |
| Net Income (ttm) | -20.99M |
| EPS (ttm) | -0.04 |
| PE Ratio (ttm) | -18.26 |
| Forward PE | -0.57 |
| Analyst | Buy |
| Ask | 0.77 |
| Volume | 72,730,001 |
| Avg. Volume (20D) | 1,341,043 |
| Open | 0.98 |
| Previous Close | 0.71 |
| Day's Range | 0.73 - 1.04 |
| 52-Week Range | 0.64 - 6.89 |
| Beta | 0.94 |
About IBIO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IBIO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IBIO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 day ago
iBio shares are trading higher after the company a...
Unlock content with
Pro Subscription
2 days ago
-7.48%
iBio shares ae trading higher after the company announced it will host a conference call to review its advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.
1 year ago · proactiveinvestors.com
iBio partners with AstralBio to develop obesity treatments using AI-driven platformiBio, an AI-driven drug developer, shares surged more than 120% after it announced it has entered into a collaboration agreement with private biotech firm AstralBio to discover, engineer and develop n...
